^
    Back
    Association details:
    Biomarker:FLT3-ITD expression
    Cancer:Acute Myelogenous Leukemia
    Drug:Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) +
    dinaciclib (MK-7965) (CDK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2022
    Title:

    276 Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD+ Acute Myeloid Leukemia

    Published date:
    11/03/2022
    Excerpt:
    Our human FLT3-ITD AML xenograft model showed a promising survival benefit and tumor burden reduction provided by combination therapies of dinaciclib/gilteritinib, brequinar/gilteritinib, and PRT808/gilteritinib over monotherapies, suggesting that the three combinations may improve the outcome of AML patients with FLT3 mutations.
    DOI:
    https://doi.org/10.1182/blood-2022-165573